Skip to content
2000
image of Molecular-targeted Therapy for Precision Medicine in Gastrointestinal Cancer: Advancement in Cancer Targeting Strategies

Abstract

Gastrointestinal (GI) cancer represent significant health challenges, affecting the digestive system with often subtle symptoms that can delay diagnosis. GI cancers account for a higher global mortality rate than any other cancer, largely due to the limited availability of highly effective treatment options.” Due to next-generation sequencing and new preclinical model tools, that we have learned more regarding its pathophysiology and molecular changes. Every molecular subtype has been characterised molecularly and new treatment targets have been found. Furthermore, tumour xenografts and organoids are grown from patients and are increasingly powerful resources for investigating GI patients' genetic evolution, identifying biomarkers, screening drugs, and conducting preclinical evaluations of personalised medicine approaches. Gastrointestinal (GI) cancer research is rapidly evolving, with recent advancements in precision medicine and immunotherapy offering new treatment options. Cutting-edge therapies, such as immune checkpoint inhibitors and targeted therapies like BRAF and HER2 inhibitors, are showing promise in treating specific types of GI cancers. These changes are making it possible for the age of precision medicine to use a mix of clinical, genome-based, and phenotype-based methods to diagnose and treat each GI patient individually. Clinical trials are exploring novel combinations of therapies to enhance survival rates and reduce side effects for patients with GI cancers, including colorectal, gastric, and pancreatic cancers. These developments are reshaping the future of gastrointestinal oncology. The purpose of this review is to study the current state of knowledge about predictive biomarkers, prospective novel targeted treatments, potential causes of conflicting trial outcomes, and the prospects for precision medicine in gastric cancer in the future

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ccdt/10.2174/0115680096333058241114064802
2025-01-10
2025-07-19

  • From This Site

    /content/journals/ccdt/10.2174/0115680096333058241114064802
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Rawla P. Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz. Gastroenterol. 2019 14 1 26 38 10.5114/pg.2018.80001
    [Google Scholar]
  2. Sahin T.K. Rizzo A. Aksoy S. Guven D.C. Prognostic Significance of the Royal Marsden Hospital (RMH) Score in Patients with Cancer: A Systematic Review and Meta-Analysis. Cancers (Basel) 2024 16 10 1835 10.3390/cancers16101835
    [Google Scholar]
  3. Iwu C.D. Iwu-Jaja C.J. Gastric Cancer Epidemiology: Current Trend and Future Direction. Hygiene 2023 3 3 256 268 10.3390/hygiene3030019
    [Google Scholar]
  4. Lai Y. Shi H. Wang Z. Feng Y. Bao Y. Li Y. Li J. Wu A. Incidence trends and disparities in Helicobacter pylori related malignancy among US adults, 2000–2019. Front. Public Health 2022 10 1056157 10.3389/fpubh.2022.1056157
    [Google Scholar]
  5. Ricci A.D. Rizzo A. Brandi G. DNA damage response alterations in gastric cancer: knocking down a new wall. Future Oncol. 2021 17 8 865 868 10.2217/fon‑2020‑0989
    [Google Scholar]
  6. Baccili Cury Megid T. Farooq A.R. Wang X. Elimova E. Gastric Cancer: Molecular Mechanisms, Novel Targets, and Immunotherapies: From Bench to Clinical Therapeutics. Cancers (Basel) 2023 15 20 5075 10.3390/cancers15205075
    [Google Scholar]
  7. Reyes V.E. Helicobacter pylori and Its Role in Gastric Cancer. Microorganisms 2023 11 5 1312 10.3390/microorganisms11051312
    [Google Scholar]
  8. Matsuoka T. Yashiro M. Molecular-targeted therapy toward precision medicine for gastrointestinal caner: Current progress and challenges. World J. Gastrointest. Oncol. 2021 13 5 366 390 10.4251/wjgo.v13.i5.366
    [Google Scholar]
  9. Dall’Olio F.G. Rizzo A. Mollica V. Massucci M. Maggio I. Massari F. Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: a meta-analysis. Immunotherapy 2021 13 3 257 270 10.2217/imt‑2020‑0179
    [Google Scholar]
  10. Waarts M.R. Stonestrom A.J. Park Y.C. Levine R.L. Targeting mutations in cancer. J. Clin. Invest. 2022 132 8 e154943 10.1172/JCI154943
    [Google Scholar]
  11. Guven D.C. Sahin T.K. Erul E. Rizzo A. Ricci A.D. Aksoy S. Yalcin S. The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Front. Mol. Biosci. 2022 9 1039121 10.3389/fmolb.2022.1039121
    [Google Scholar]
  12. Rizzo A. Santoni M. Mollica V. Logullo F. Rosellini M. Marchetti A. Faloppi L. Battelli N. Massari F. Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study. Expert Opin. Drug Metab. Toxicol. 2021 17 12 1455 1466 10.1080/17425255.2021.2029405
    [Google Scholar]
  13. Guan W.L. He Y. Xu R.H. Gastric cancer treatment: recent progress and future perspectives. J. Hematol. Oncol. 2023 16 1 57 [Internet]. 10.1186/s13045‑023‑01451‑3
    [Google Scholar]
  14. Wang F. Ba Y. Treatment strategies for patients with HER2-positive gastric cancer. Cancer Biol. Med. 2024 20 12 934 941 10.20892/j.issn.2095‑3941.2023.0480
    [Google Scholar]
  15. Wee P. Wang Z. Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. Cancers (Basel) 2017 9 5 52 [PMID: 28513565 DOI: 10.3390/cancers9050052]. 10.3390/cancers9050052
    [Google Scholar]
  16. Lièvre A. Bachet J.B. Boige V. Cayre A. Le Corre D. Buc E. Ychou M. Bouché O. Landi B. Louvet C. André T. Bibeau F. Diebold M.D. Rougier P. Ducreux M. Tomasic G. Emile J.F. Penault-Llorca F. Laurent-Puig P. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 2008 26 3 374 379 [PMID: 18202412 DOI: 10.1200/JCO.2007.12.5906]. 10.1200/JCO.2007.12.5906
    [Google Scholar]
  17. Amado R.G. Wolf M. Peeters M. Van Cutsem E. Siena S. Freeman D.J. Juan T. Sikorski R. Suggs S. Radinsky R. Patterson S.D. Chang D.D. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008 26 10 1626 1634 [PMID: 18316791 DOI: 10.1200/JCO.2007.14.7116]. 10.1200/JCO.2007.14.7116
    [Google Scholar]
  18. Zhao B. Wang L. Qiu H. Zhang M. Sun L. Peng P. Yu Q. Yuan X. Mechanisms of resistance to anti-EGFR therapy in colorectal cancer. Oncotarget 2017 8 3 3980 4000 [PMID: 28002810 DOI: 10.18632/oncotarget.14012]. 10.18632/oncotarget.14012
    [Google Scholar]
  19. Montagut C. Argilés G. Ciardiello F. Poulsen T.T. Dienstmann R. Kragh M. Kopetz S. Lindsted T. Ding C. Vidal J. Clausell-Tormos J. Siravegna G. Sánchez-Martín F.J. Koefoed K. Pedersen M.W. Grandal M.M. Dvorkin M. Wyrwicz L. Rovira A. Cubillo A. Salazar R. Desseigne F. Nadal C. Albanell J. Zagonel V. Siena S. Fumi G. Rospo G. Nadler P. Horak I.D. Bardelli A. Tabernero J. Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses. JAMA Oncol. 2018 4 4 e175245 [PMID: 29423521 DOI: 10.1001/jamaoncol.2017.5245]. 10.1001/jamaoncol.2017.5245
    [Google Scholar]
  20. Bettegowda C. Sausen M. Leary R.J. Kinde I. Wang Y. Agrawal N. Bartlett B.R. Wang H. Luber B. Alani R.M. Antonarakis E.S. Azad N.S. Bardelli A. Brem H. Cameron J.L. Lee C.C. Fecher L.A. Gallia G.L. Gibbs P. Le D. Giuntoli R.L. Goggins M. Hogarty M.D. Holdhoff M. Hong S.M. Jiao Y. Juhl H.H. Kim J.J. Siravegna G. Laheru D.A. Lauricella C. Lim M. Lipson E.J. Marie S.K. Netto G.J. Oliner K.S. Olivi A. Olsson L. Riggins G.J. Sartore-Bianchi A. Schmidt K. Shih lM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA Jr. Detection of circulating tumor DNA in early- and late- stage human malignancies. Sci. Transl. Med. 2014 6 224ra24 [PMID: 24553385 DOI: 10.1126/scitranslmed.3007094].
    [Google Scholar]
  21. Strickler J.H. Loree J.M. Ahronian L.G. Parikh A.R. Niedzwiecki D. Pereira A.A.L. McKinney M. Korn W.M. Atreya C.E. Banks K.C. Nagy R.J. Meric-Bernstam F. Lanman R.B. Talasaz A. Tsigelny I.F. Corcoran R.B. Kopetz S. Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer. Cancer Discov. 2018 8 2 164 173 [PMID: 29196463 DOI: 10.1158/2159-8290.CD-17-1009]. 10.1158/2159‑8290.CD‑17‑1009
    [Google Scholar]
  22. Siravegna G. Mussolin B. Buscarino M. Corti G. Cassingena A. Crisafulli G. Ponzetti A. Cremolini C. Amatu A. Lauricella C. Lamba S. Hobor S. Avallone A. Valtorta E. Rospo G. Medico E. Motta V. Antoniotti C. Tatangelo F. Bellosillo B. Veronese S. Budillon A. Montagut C. Racca P. Marsoni S. Falcone A. Corcoran R.B. Di Nicolantonio F. Loupakis F. Siena S. Sartore-Bianchi A. Bardelli A. Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat. Med. 2015 21 7 827 [PMID: 26151329 DOI: 10.1038/nm0715-827b]. 10.1038/nm0715‑827b
    [Google Scholar]
  23. Pietrantonio F. Vernieri C. Siravegna G. Mennitto A. Berenato R. Perrone F. Gloghini A. Tamborini E. Lonardi S. Morano F. Picciani B. Busico A. Volpi C.C. Martinetti A. Battaglin F. Bossi I. Pellegrinelli A. Milione M. Cremolini C. Di Bartolomeo M. Bardelli A. de Braud F. Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. Clin. Cancer Res. 2017 23 10 2414 2422 [PMID: 27780856 DOI:10.1158/1078-0432.CCR-16-1863]. 10.1158/1078‑0432.CCR‑16‑1863
    [Google Scholar]
  24. Russo M. Siravegna G. Blaszkowsky L.S. Corti G. Crisafulli G. Ahronian L.G. Mussolin B. Kwak E.L. Buscarino M. Lazzari L. Valtorta E. Truini M. Jessop N.A. Robinson H.E. Hong T.S. Mino-Kenudson M. Di Nicolantonio F. Thabet A. Sartore-Bianchi A. Siena S. Iafrate A.J. Bardelli A. Corcoran R.B. Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. Cancer Discov. 2016 6 2 147 153 [PMID: 26644315 DOI: 10.1158/2159-8290.CD-15-1283]. 10.1158/2159‑8290.CD‑15‑1283
    [Google Scholar]
  25. Tran B. Kopetz S. Tie J. Gibbs P. Jiang Z.Q. Lieu C.H. Agarwal A. Maru D.M. Sieber O. Desai J. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011 117 20 4623 4632 [PMID: 21456008 DOI: 10.1002/cncr.26086]. 10.1002/cncr.26086
    [Google Scholar]
  26. Karoulia Z. Gavathiotis E. Poulikakos P.I. New perspectives for targeting RAF kinase in human cancer. Nat. Rev. Cancer 2017 17 11 676 691 [PMID: 28984291 DOI: 10.1038/nrc.2017.79]. 10.1038/nrc.2017.79
    [Google Scholar]
  27. Laurent-Puig P. Cayre A. Manceau G. Buc E. Bachet J.B. Lecomte T. Rougier P. Lievre A. Landi B. Boige V. Ducreux M. Ychou M. Bibeau F. Bouché O. Reid J. Stone S. Penault-Llorca F. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J. Clin. Oncol. 2009 27 35 5924 5930 [PMID: 19884556 DOI: 10.1200/JCO.2008.21.6796]. 10.1200/JCO.2008.21.6796
    [Google Scholar]
  28. Loupakis F. Ruzzo A. Cremolini C. Vincenzi B. Salvatore L. Santini D. Masi G. Stasi I. Canestrari E. Rulli E. Floriani I. Bencardino K. Galluccio N. Catalano V. Tonini G. Magnani M. Fontanini G. Basolo F. Falcone A. Graziano F. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br. J. Cancer 2009 101 4 715 721 [PMID: 19603018 DOI: 10.1038/sj.bjc.6605177]. 10.1038/sj.bjc.6605177
    [Google Scholar]
  29. Roth A.D. Tejpar S. Delorenzi M. Yan P. Fiocca R. Klingbiel D. Dietrich D. Biesmans B. Bodoky G. Barone C. Aranda E. Nordlinger B. Cisar L. Labianca R. Cunningham D. Van Cutsem E. Bosman F. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J. Clin. Oncol. 2010 28 3 466 474 [PMID: 20008640 DOI: 10.1200/JCO.2009.23.3452]. 10.1200/JCO.2009.23.3452
    [Google Scholar]
  30. Prahallad A. Sun C. Huang S. Di Nicolantonio F. Salazar R. Zecchin D. Beijersbergen R.L. Bardelli A. Bernards R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012 483 7387 100 103 [PMID: 22281684 DOI: 10.1038/nature10868]. 10.1038/nature10868
    [Google Scholar]
  31. Corcoran R.B. André T. Atreya C.E. Schellens J.H.M. Yoshino T. Bendell J.C. Hollebecque A. McRee A.J. Siena S. Middleton G. Muro K. Gordon M.S. Tabernero J. Yaeger R. O’Dwyer P.J. Humblet Y. De Vos F. Jung A.S. Brase J.C. Jaeger S. Bettinger S. Mookerjee B. Rangwala F. Van Cutsem E. Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer. Cancer Discov. 2018 8 4 428 443 [PMID: 29431699 DOI: 10.1158/2159-8290.CD-17-1226]. 10.1158/2159‑8290.CD‑17‑1226
    [Google Scholar]
  32. Richman S.D. Southward K. Chambers P. Cross D. Barrett J. Hemmings G. Taylor M. Wood H. Hutchins G. Foster J.M. Oumie A. Spink K.G. Brown S.R. Jones M. Kerr D. Handley K. Gray R. Seymour M. Quirke P. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J. Pathol. 2016 238 4 562 570 [PMID: 26690310 DOI: 10.1002/path.4679]. 10.1002/path.4679
    [Google Scholar]
  33. Shitara K. Bang Y.J. Iwasa S. Sugimoto N. Ryu M.H. Sakai D. Chung H.C. Kawakami H. Yabusaki H. Lee J. Saito K. Kawaguchi Y. Kamio T. Kojima A. Sugihara M. Yamaguchi K. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N. Engl. J. Med. 2020 382 25 2419 2430 10.1056/NEJMoa2004413
    [Google Scholar]
  34. Hainsworth J.D. Meric-Bernstam F. Swanton C. Hurwitz H. Spigel D.R. Sweeney C. Burris H.A. Bose R. Yoo B. Stein A. Beattie M. Kurzrock R. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. J. Clin. Oncol. 2018 36 6 536 542 [PMID: 29320312 DOI: 10.1200/JCO.2017.75.3780]. 10.1200/JCO.2017.75.3780
    [Google Scholar]
  35. Strickler J.H. Cercek A. Siena S. André T. Ng K. Van Cutsem E. Wu C. Paulson A.S. Hubbard J.M. Coveler A.L. Fountzilas C. Kardosh A. Kasi P.M. Lenz H.J. Ciombor K.K. Elez E. Bajor D.L. Cremolini C. Sanchez F. Stecher M. Feng W. Bekaii-Saab T.S. Van Cutsem E. Peeters M. Van den Evnde M. André T. Borg C. Sarabi M. Ghiringhelli F. Chibaudel B. Siena S. Cremolini C. Zampino M.G. Elez E. Keranen S.R. Salazar R. Alfonso P. Strickler J.H. Cercek A. Ng K. Wu C. Paulson A.S. Hubbard J.M. Coveler A.L. Fountzilas C. Kardosh A. Kasi P.M. Lenz H-J. Ciombor K.K. Bajor D.L. Bekaii-Saab T.S. Gbolahan O. Boland P. Berg D. Sanchez F. Goggins T. Saeed A. Burris H. Bendell J. Outlaw D. Tafur I. Shergill A. Catenacci D. Gong J. Garrido-Laguna I. Finley G. Weinberg B. Shields A. Philip P. Turk A. Nguyen A. Braiteh F. Patel V. Harwin W. Anderson I. Kundra A. Chen C. Ford J. Kundranda M. Nguyen D. Ratnam S. Richards D. Nallapareddy S. Beeram S. McKenney S. Shao S. MOUNTAINEER investigators Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 2023 24 5 496 508 10.1016/S1470‑2045(23)00150‑X
    [Google Scholar]
  36. Fuchs C.S. Doi T. Jang R.W. Muro K. Satoh T. Machado M. Sun W. Jalal S.I. Shah M.A. Metges J.P. Garrido M. Golan T. Mandala M. Wainberg Z.A. Catenacci D.V. Ohtsu A. Shitara K. Geva R. Bleeker J. Ko A.H. Ku G. Philip P. Enzinger P.C. Bang Y-J. Levitan D. Wang J. Rosales M. Dalal R.P. Yoon H.H. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 clinical keynote-059 trial. JAMA Oncol. 2018 4 5 e180013 [CrossRef]. 10.1001/jamaoncol.2018.0013
    [Google Scholar]
  37. Shitara K. Özgüroğlu M. Bang Y-J. Di Bartolomeo M. Mandalà M. Ryu M-H. Fornaro L. Olesiński T. Caglevic C. Chung H.C. Muro K. Goekkurt E. Mansoor W. McDermott R.S. Shacham-Shmueli E. Chen X. Mayo C. Kang S.P. Ohtsu A. Fuchs C.S. Lerzo G. O’Connor J.M. Mendez G.A. Lynam J. Tebbutt N. Wong M. Strickland A. Karapetis C. Goldstein D. Vasey P. Van Laethem J-L. Van Cutsem E. Berry S. Vincent M. Muller B. Rey F. Zambrano A. Guerra J. Krogh M. Baeksgaard L. Yilmaz M. Elme A. Magi A. Auvinen P. Alanko T. Moehler M. Kunzmann V. Seufferlein T. Thuss-Patience P. Goekkurt E. Hoehler T. Haag G. Al-Batran S-E. Castro H. Lopez K. Aguilar Vasquez M. Sandoval M. Lam K.O. Cuffe S. Kelly C. Geva R. Shacham-Shmueli E. Hubert A. Beny A. Brenner B. Giuseppe A. Falcone A. Maiello E. Passalacqua R. Montesarchio V. Hara H. Chin K. Nishina T. Komatsu Y. Machida N. Hironaka S. Satoh T. Tamura T. Sugimoto N. Cho H. Omuro Y. Kato K. Goto M. Hyodo I. Yoshida K. Baba H. Esaki T. Furuse J. Wan Mohammed W.Z. Hernandez Hernandez C. Casas Garcia J. Dominguez Andrade A. Clarke K. Hjortland G. Glenjen N. Kubiatowski T. Jacek J. Wojtukiewicz M. Lazarev S. Lancukhay Y. Afanasayev S. Moiseyenko V. Kostorov V. Protsenko S. Shirinkin V. Sakaeva D. Fadeeva N. Yong W.P. Ng C.H.M. Robertson B. Rapaport B. Cohen G. Dreosti L. Ruff P. Jacobs C. Landers G. Szpak W. Roh S-Y. Lee J. Kim Y.H. Bang Y-J. Chung H.C. Ryu M-H. Alsina Maqueda M. Longo Munoz F. Cervantes Aguilar A. Aranda Aguilar E. Garcia Alfonso P. Rivera F. Feliu Batle J. Pazo Cid R. Yeh K-H. Chen J-S. Chao Y. Yen C-J. Özgüroğlu M. Kara O. Yalcin S. Hochhauser D. Chau I. Benson A. Shankaran V. Shaib W. Philip P. Sharma V. Siegel R. Sun W. Wainberg Z. George B. Bullock A. Myrick S. Faruol J. Siegel R. Larson T. Becerra C. Ratnam S. Richards D.A. Riche S.L. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet 2018 392 10142 123 133 [CrossRef]. 10.1016/S0140‑6736(18)31257‑1
    [Google Scholar]
  38. Shitara K. Van Cutsem E. Bang Y.J. Fuchs C. Wyrwicz L. Lee K.W. Kudaba I. Garrido M. Chung H.C. Lee J. Castro H.R. Mansoor W. Braghiroli M.I. Karaseva N. Caglevic C. Villanueva L. Goekkurt E. Satake H. Enzinger P. Alsina M. Benson A. Chao J. Ko A.H. Wainberg Z.A. Kher U. Shah S. Kang S.P. Tabernero J. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer. JAMA Oncol. 2020 6 10 1571 1580 [CrossRef]. 10.1001/jamaoncol.2020.3370
    [Google Scholar]
  39. Wainberg Z.A. Fuchs C.S. Tabernero J. Shitara K. Muro K. Van Cutsem E. Bang Y.J. Chung H.C. Yamaguchi K. Varga E. Chen J-S. Hochhauser D. Thuss-Patience P.C. Al-Batran S-E. Garrido M. Kher U. Shih C-S. Shah S. Bhagia P. Chao J. Efficacy of pembrolizumab (pembro) monotherapy versus chemotherapy for PD-L1–positive (CPS ≥10) advanced G/GEJ cancer in the phase II KEYNOTE-059 (cohort 1) and phase III KEYNOTE-061 and KEYNOTE-062 studies. J. Clin. Oncol. 2020 38 4_suppl 427 [CrossRef]. 10.1200/JCO.2020.38.4_suppl.427
    [Google Scholar]
  40. Moehler M. Dvorkin M. Boku N. Özgüroğlu M. Ryu M-H. Muntean A.S. Lonardi S. Nechaeva M. Bragagnoli A.C. Coşkun H.S. Cubillo Gracian A. Takano T. Wong R. Safran H. Vaccaro G.M. Wainberg Z.A. Silver M.R. Xiong H. Hong J. Taieb J. Bang Y-J. Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100. J. Clin. Oncol. 2021 39 9 966 977 [CrossRef]. 10.1200/JCO.20.00892
    [Google Scholar]
  41. Fong C. Patel B. Peckitt C. Bourmpaki E. von Loga K. Begum R. Davidson M. Anandappa G. Cafferkey C. Watkins D.J. Rao S. Waddell T. Wadsley J. Coxon F. Roques T. Morgan C. Rees C. Starling N. Chau I. Cunningham D. Maintenance durvalumab after first-line platinum-based chemotherapy in advanced oesophago-gastric (OG) adenocarcinoma: Results from the PLATFORM trial. J. Clin. Oncol. 2021 39 15_suppl 4015 [CrossRef]. 10.1200/JCO.2021.39.15_suppl.4015
    [Google Scholar]
  42. Janjigian Y.Y. Shitara K. Moehler M. Garrido M. Salman P. Shen L. Wyrwicz L. Yamaguchi K. Skoczylas T. Campos Bragagnoli A. Liu T. Schenker M. Yanez P. Tehfe M. Kowalyszyn R. Karamouzis M.V. Bruges R. Zander T. Pazo-Cid R. Hitre E. Feeney K. Cleary J.M. Poulart V. Cullen D. Lei M. Xiao H. Kondo K. Li M. Ajani J.A. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 2021 398 10294 27 40 [CrossRef]. 10.1016/S0140‑6736(21)00797‑2
    [Google Scholar]
  43. Yoon H.H. Jin Z. Kour O. Kankeu Fonkoua L.A. Shitara K. Gibson M.K. Prokop L.J. Moehler M. Kang Y.K. Shi Q. Ajani J.A. Association of pd-l1 expression and other variables with benefit from immune checkpoint inhibition in advanced gastroesophageal cancer: Systematic review and meta-analysis of 17 phase 3 randomized clinical trials. JAMA Oncol. 2022 8 10 1456 1465 [CrossRef]. 10.1001/jamaoncol.2022.3707
    [Google Scholar]
  44. Park Y. Koh J. Na H.Y. Kwak Y. Lee K.W. Ahn S.H. Park D.J. Kim H.H. Lee H.S. PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs. Cancer Res. Treat. 2020 52 3 661 670 [CrossRef]. 10.4143/crt.2019.718
    [Google Scholar]
  45. Ahn S. Kim K.M. PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy. Mod. Pathol. 2021 34 9 1719 1727 [CrossRef]. 10.1038/s41379‑021‑00823‑9
    [Google Scholar]
  46. Chu L. Chen Y. Liu Q. Liang F. Wang S. Liu Q. Yu H. Wu X. Zhang J. Deng J. Ai D. Zhu Z. Nie Y. Zhao K. A phase II study of apatinib in patients with chemotherapy-refractory esophageal squamous cell carcinoma (ESO-Shanghai 11). Oncologist 2015 26 6 e925 e935 10.1002/onco.13668
    [Google Scholar]
  47. Hewitt L.C. Inam I.Z. Saito Y. Yoshikawa T. Quaas A. Hoelscher A. Bollschweiler E. Fazzi G.E. Melotte V. Langley R.E. Nankivell M. Cunningham D. Allum W. Hutchins G.G. Grabsch H.I. Epstein-Barr virus and mismatch repair deficiency status differ between oesophageal and gastric cancer: A large multi-centre study. Eur. J. Cancer 2018 94 104 114 [CrossRef]. 10.1016/j.ejca.2018.02.014
    [Google Scholar]
  48. Pietrantonio F. Randon G. Di Bartolomeo M. Luciani A. Chao J. Smyth E.C. Petrelli F. Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials. ESMO Open 2021 6 1 100036 [CrossRef]. 10.1016/j.esmoop.2020.100036
    [Google Scholar]
  49. Yoon H.H. Jin Z. Kour O. Shitara K. Gibson M.K. Prokop L. Kang Y.K. Shi Q. Ajani J.A. Association of magnitude and consistency of PD-L1 expression and other variables associated with benefit from immune checkpoint inhibition (ICI): Systematic review and meta-analysis of 14 phase 3 trials in advanced gastroesophageal cancer (GEC). J. Clin. Oncol. 2022 40 4_suppl 344 [CrossRef]. 10.1200/JCO.2022.40.4_suppl.344
    [Google Scholar]
  50. Kwon M. An M. Klempner S.J. Lee H. Kim K.M. Sa J.K. Cho H.J. Hong J.Y. Lee T. Min Y.W. Kim T.J. Min B-H. Park W-Y. Kang W.K. Kim K-T. Kim S.T. Lee J. Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability–High Gastric Cancer. Cancer Discov. 2021 11 9 2168 2185 [CrossRef]. 10.1158/2159‑8290.CD‑21‑0219
    [Google Scholar]
  51. Kawakami H. Hironaka S. Esaki T. Chayama K. Tsuda M. Sugimoto N. Kadowaki S. Makiyama A. Machida N. Hirano H. Hirata K. Hara H. Yabusaki H. Komatsu Y. Muro K. An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7). Cancers (Basel) 2021 13 4 805 [CrossRef]. 10.3390/cancers13040805
    [Google Scholar]
  52. Marabelle A. Fakih M.G. Lopez J. Shah M. Shapira-Frommer R. Nakagawa K. Chung H.C. Kindler H.L. Lopez-Martin J.A. Miller W. Italiano A. Kao S. Piha-Paul S.A. Delord J-P. McWilliams R.R. Aurora-Garg D. Chen M. Jin F. Norwood K. Bang Y-J. Association of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158. Ann. Oncol. 2019 30 v477 v478 [CrossRef]. 10.1093/annonc/mdz253.018
    [Google Scholar]
  53. Shitara K. Özgüroğlu M. Bang Y-J. Di Bartolomeo M. Mandalà M. Ryu M-H. Caglevic C. Chung H.C. Muro K. Van Cutsem E. Kobie J. Cristescu R. Aurora-Garg D. Lu J. Shih C-S. Adelberg D. Cao Z.A. Fuchs C.S. Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma. Ann. Oncol. 2021 32 9 1127 1136 [CrossRef]. 10.1016/j.annonc.2021.05.803
    [Google Scholar]
  54. Curigliano G. Shah R.R. Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology. Drug Saf. 2019 42 2 247 262 [PMID: 30649751 DOI: 10.1007/s40264-018-0778-4]. 10.1007/s40264‑018‑0778‑4
    [Google Scholar]
  55. Weldon Gilcrease G. Stenehjem D.D. Wade M.L. Weis J. McGregor K. Whisenant J. Boucher K.M. Thorne K. Orgain N. Garrido-Laguna I. Sharma S. Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first–line treatment of metastatic colorectal cancer. Invest. New Drugs 2019 37 3 482 489 [PMID: 30302599 DOI: 10.1007/s10637-018-0645-2]. 10.1007/s10637‑018‑0645‑2
    [Google Scholar]
  56. van Geel R.M.J.M. Tabernero J. Elez E. Bendell J.C. Spreafico A. Schuler M. Yoshino T. Delord J.P. Yamada Y. Lolkema M.P. Faris J.E. Eskens F.A.L.M. Sharma S. Yaeger R. Lenz H.J. Wainberg Z.A. Avsar E. Chatterjee A. Jaeger S. Tan E. Maharry K. Demuth T. Schellens J.H.M. A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF -Mutant Colorectal Cancer. Cancer Discov. 2017 7 6 610 619 [PMID: 28363909 DOI:10.1158/2159-8290.CD-16-0795]. 10.1158/2159‑8290.CD‑16‑0795
    [Google Scholar]
  57. Lorenzen S. Knorrenschild J.R. Pauligk C. Becker S. Seraphin J. Patience P. Kopp H.G. Dechow T. Vogel A. Luley K.B. Pink D. Stahl M. Kullmann F. Hebart H. Siveke J. Egger M. Homann N. Probst S. Goetze T.O. Al-Batran S.E. Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Int. J. Cancer 2020 147 2493 2502 10.1002/ijc.33025
    [Google Scholar]
  58. Fritsch C. Huang A. Chatenay-Rivauday C. Schnell C. Reddy A. Liu M. Kauffmann A. Guthy D. Erdmann D. De Pover A. Furet P. Gao H. Ferretti S. Wang Y. Trappe J. Brachmann S.M. Maira S.M. Wilson C. Boehm M. Garcia-Echeverria C. Chene P. Wiesmann M. Cozens R. Lehar J. Schlegel R. Caravatti G. Hofmann F. Sellers W.R. Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol. Cancer Ther. 2014 13 5 1117 1129 [PMID: 24608574 DOI: 10.1158/1535-7163.MCT-13-0865]. 10.1158/1535‑7163.MCT‑13‑0865
    [Google Scholar]
  59. Davies B.R. Greenwood H. Dudley P. Crafter C. Yu D.H. Zhang J. Li J. Gao B. Ji Q. Maynard J. Ricketts S.A. Cross D. Cosulich S. Chresta C.C. Page K. Yates J. Lane C. Watson R. Luke R. Ogilvie D. Pass M. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol. Cancer Ther. 2012 11 4 873 887 [PMID: 22294718 DOI: 10.1158/1535-7163.MCT-11-0824-T]. 10.1158/1535‑7163.MCT‑11‑0824‑T
    [Google Scholar]
  60. Gonzalez-Angulo A.M. Meric-Bernstam F. Chawla S. Falchook G. Hong D. Akcakanat A. Chen H. Naing A. Fu S. Wheler J. Moulder S. Helgason T. Li S. Elias I. Desai N. Kurzrock R. Weekly nab- Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial. Clin. Cancer Res. 2013 19 19 5474 5484 [PMID: 24089446 DOI: 10.1158/1078-0432.CCR-12-3110]. 10.1158/1078‑0432.CCR‑12‑3110
    [Google Scholar]
  61. Dimova I. Popivanov G. Djonov V. Angiogenesis in cancer - general pathways and their therapeutic implications. J. BUON 2014 19 15 21 [PMID: 24659637].
    [Google Scholar]
  62. Battaglin F. Puccini A. Intini R. Schirripa M. Ferro A. Bergamo F. Lonardi S. Zagonel V. Lenz H.J. Loupakis F. The role of tumor angiogenesis as a therapeutic target in colorectal cancer. Expert Rev. Anticancer Ther. 2018 18 3 251 266 [PMID: 29338550 DOI: 10.1080/14737140.2018.1428092]. 10.1080/14737140.2018.1428092
    [Google Scholar]
  63. Kabbinavar F.F. Hambleton J. Mass R.D. Hurwitz H.I. Bergsland E. Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/Leucovorin improves survival for patients with metastatic colorectal cancer. J. Clin. Oncol. 2005 23 16 3706 3712 [PMID: 15867200 DOI: 10.1200/JCO.2005.00.232]. 10.1200/JCO.2005.00.232
    [Google Scholar]
  64. Pineda E. Salud A. Vila-Navarro E. Safont M.J. Llorente B. Aparicio J. Vera R. Escudero P. Casado E. Bosch C. Bohn U. Pérez-Carrión R. Carmona A. Ayuso J.R. Ripollés T. Bouzas R. Gironella M. García-Albéniz X. Feliu J. Maurel J. Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial. Tumour Biol. 2017 39 6 [PMID: 28621236 DOI: 10.1177/1010428317705509]. 10.1177/1010428317705509
    [Google Scholar]
  65. Carbone C. Piro G. Simionato F. Ligorio F. Cremolini C. Loupakis F. Alì G. Rossini D. Merz V. Santoro R. Zecchetto C. Zanotto M. Di Nicolantonio F. Bardelli A. Fontanini G. Tortora G. Melisi D. Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients. Clin. Cancer Res. 2017 23 15 4312 4322 [PMID: 28298545 DOI: 10.1158/1078-0432.CCR-16-3153]. 10.1158/1078‑0432.CCR‑16‑3153
    [Google Scholar]
  66. Mawalla B. Yuan X. Luo X. Chalya P.L. Treatment outcome of anti-angiogenesis through VEGF-pathway in the management of gastric cancer: a systematic review of phase II and III clinical trials. BMC Res. Notes 2018 11 1 21 [PMID: 29329598 DOI: 10.1186/s13104-018-3137-8]. 10.1186/s13104‑018‑3137‑8
    [Google Scholar]
  67. De Vita F. Borg C. Farina G. Geva R. Carton I. Cuku H. Wei R. Muro K. Ramucirumab and paclitaxel in patients with gastric cancer and prior trastuzumab: subgroup analysis from RAINBOW study. Future Oncol. 2019 15 23 2723 2731 10.2217/fon‑2019‑0243
    [Google Scholar]
  68. Goel G. Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a “me too” drug? Cancer Manag. Res. 2018 10 425 437 10.2147/CMAR.S88825
    [Google Scholar]
  69. Shitara K. Yamanaka T. Denda T. Tsuji Y. Shinozaki K. Komatsu Y. Kobayashi Y. Furuse J. Okuda H. Asayama M. Akiyoshi K. Kagawa Y. Kato T. Oki E. Ando T. Hagiwara Y. Ohashi Y. Yoshino T. REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients. Ann. Oncol. 2019 30 2 259 265 [PMID: 30508156 DOI: 10.1093/annonc/mdy526]. 10.1093/annonc/mdy526
    [Google Scholar]
  70. Pavlakis N. Sjoquist K.M. Martin A.J. Tsobanis E. Yip S. Kang Y.K. Bang Y.J. Alcindor T. O’Callaghan C.J. Burnell M.J. Tebbutt N.C. Rha S.Y. Lee J. Cho J.Y. Lipton L.R. Wong M. Strickland A. Kim J.W. Zalcberg J.R. Simes J. Goldstein D. Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial. J. Clin. Oncol. 2016 34 23 2728 2735 [PMID: 27325864 DOI: 10.1200/JCO.2015.65.1901]. 10.1200/JCO.2015.65.1901
    [Google Scholar]
  71. Li J. Zhao X. Chen L. Guo H. Lv F. Jia K. Yv K. Wang F. Li C. Qian J. Zheng C. Zuo Y. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer 2010 10 1 529 [PMID: 20923544 DOI: 10.1186/1471-2407-10-529]. 10.1186/1471‑2407‑10‑529
    [Google Scholar]
  72. Wang F. Yuan X. Jia J. Bi X. Zhou Z. Zhou Q. Li X. Luo C. Deng M. Yi L. Li Y. Lu J. Su W. Chen H. Zhu Y. Wang S. Apatinib Monotherapy for Chemotherapy-Refractory Metastatic Colorectal Cancer: A Multi-centre, Single-Arm, Prospective Study. Sci. Rep. 2020 10 1 6058 [PMID: 32269247 DOI: 10.1038/s41598-020-62961-5]. 10.1038/s41598‑020‑62961‑5
    [Google Scholar]
  73. Curtin N.J. The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and Serendipity. Cancers (Basel). 2020 Feb 29;12(3):564. Xu Z, Hu C, Chen S, Zhang C, Yu J, Wang X, Lv H, Cheng X. Apatinib enhances chemosensitivity of gastric cancer to paclitaxel and 5-fluorouracil. Cancer Manag. Res. 2019 11 4905 4915 [PMID: 31213909 DOI: 10.2147/CMAR.S196372].
    [Google Scholar]
  74. Bellesoeur A. Carton E. Alexandre J. Goldwasser F. Huillard O. Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy. Drug Des. Devel. Ther. 2017 11 2801 2811 [PMID: 29033542 DOI: 10.2147/DDDT.S109640]. 10.2147/DDDT.S109640
    [Google Scholar]
  75. Zhang Y. Zou J.Y. Wang Z. Wang Y. Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer. Cancer Manag. Res. 2019 11 7787 7803 [PMID: 31496821 DOI: 10.2147/CMAR.S215533]. 10.2147/CMAR.S215533
    [Google Scholar]
  76. Li J. Qin S. Xu R.H. Shen L. Xu J. Bai Y. Yang L. Deng Y. Chen Z. Zhong H. Pan H. Guo W. Shu Y. Yuan Y. Zhou J. Xu N. Liu T. Ma D. Wu C. Cheng Y. Chen D. Li W. Sun S. Yu Z. Cao P. Chen H. Wang J. Wang S. Wang H. Fan S. Hua Y. Su W. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer. JAMA 2018 319 24 2486 2496 [PMID: 29946728 DOI: 10.1001/jama.2018.7855]. 10.1001/jama.2018.7855
    [Google Scholar]
  77. Catenacci D.V.T. Rasco D. Lee J. Rha S.Y. Lee K.W. Bang Y.J. Bendell J. Enzinger P. Marina N. Xiang H. Deng W. Powers J. Wainberg Z.A. Phase I. Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma. J. Clin. Oncol. 2020 38 21 2418 2426 [PMID: 32167861 DOI: 10.1200/JCO.19.01834]. 10.1200/JCO.19.01834
    [Google Scholar]
  78. Montazeri K. Bellmunt J. Erdafitinib for the treatment of metastatic bladder cancer. Expert Rev. Clin. Pharmacol. 2020 13 1 1 6 [PMID: 31810398 DOI: 10.1080/17512433.2020.1702025]. 10.1080/17512433.2020.1702025
    [Google Scholar]
  79. Luo J. Chen X.Q. Li P. The Role of TGF-β and Its Receptors in Gastrointestinal Cancers. Transl. Oncol. 2019 12 3 475 484 [PMID: 30594036 DOI: 10.1016/j.tranon.2018.11.010]. 10.1016/j.tranon.2018.11.010
    [Google Scholar]
  80. Yashiro M. Hirakawa K. Boland C.R. Mutations in TGFbeta-RII and BAXmediate tumor progression in the later stages of colorectal cancer with microsatellite instability. BMC Cancer 2010 10 1 303 [PMID: 20565851 DOI: 10.1186/1471-2407-10-303]. 10.1186/1471‑2407‑10‑303
    [Google Scholar]
  81. Wosiak A. Wodziński D. Kolasa M. Sałagacka-Kubiak A. Balcerczak E. SMAD-4 gene expression in human colorectal cancer: Comparison with some clinical and pathological parameters. Pathol. Res. Pract. 2017 213 1 45 49 [PMID: 27914767 DOI: 10.1016/j.prp.2016.10.013]. 10.1016/j.prp.2016.10.013
    [Google Scholar]
  82. Jochems C. Tritsch S.R. Pellom S.T. Su Z. Soon-Shiong P. Wong H.C. Gulley J.L. Schlom J. Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824). Oncotarget 2017 8 43 75217 75231 [PMID: 29088859 DOI: 10.18632/oncotarget.20680]. 10.18632/oncotarget.20680
    [Google Scholar]
  83. Strauss J. Heery C.R. Schlom J. Madan R.A. Cao L. Kang Z. Lamping E. Marté J.L. Donahue R.N. Grenga I. Cordes L. Christensen O. Mahnke L. Helwig C. Gulley J.L. Phase I. Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors. Clin. Cancer Res. 2018 24 6 1287 1295 [PMID: 29298798 DOI:10.1158/1078-0432.CCR-17-2653]. 10.1158/1078‑0432.CCR‑17‑2653
    [Google Scholar]
  84. Katz L.H. Likhter M. Jogunoori W. Belkin M. Ohshiro K. Mishra L. TGF-β signaling in liver and gastrointestinal cancers. Cancer Lett. 2016 379 2 166 172 [PMID: 27039259 DOI: 10.1016/j.canlet.2016.03.033]. 10.1016/j.canlet.2016.03.033
    [Google Scholar]
  85. Konstorum A. Lowengrub J.S. Activation of the HGF/c-Met axis in the tumor microenvironment: A multispecies model. J. Theor. Biol. 2018 439 86 99 10.1016/j.jtbi.2017.11.025
    [Google Scholar]
  86. Fuse N. Kuboki Y. Kuwata T. Nishina T. Kadowaki S. Shinozaki E. Machida N. Yuki S. Ooki A. Kajiura S. Kimura T. Yamanaka T. Shitara K. Nagatsuma A.K. Yoshino T. Ochiai A. Ohtsu A. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients. Gastric Cancer 2016 19 1 183 191 [PMID: 25682441 DOI: 10.1007/s10120-015-0471-6]. 10.1007/s10120‑015‑0471‑6
    [Google Scholar]
  87. Shitara K. Kim T.M. Yokota T. Goto M. Satoh T. Ahn J.H. Kim H.S. Assadourian S. Gomez C. Harnois M. Hamauchi S. Kudo T. Doi T. Bang Y.J. Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer. Oncotarget 2017 8 79546 79555 10.18632/oncotarget.18554
    [Google Scholar]
  88. Amé J.C. Spenlehauer C. de Murcia G. The PARP superfamily. BioEssays 2004 26 8 882 893 [PMID:15273990 DOI: 10.1002/bies.20085]. 10.1002/bies.20085
    [Google Scholar]
  89. Kubota E. Williamson C.T. Ye R. Elegbede A. Peterson L. Lees-Miller S.P. Bebb D.G. Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines. Cell Cycle 2014 13 13 2129 2137 [PMID: 24841718 DOI: 10.4161/cc.29212]. 10.4161/cc.29212
    [Google Scholar]
  90. Curtin N.J. The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and Serendipity. Cancers (Basel). 2020 Feb 29;12(3):564. Shirley M. Rucaparib: A Review in Ovarian Cancer. Target. Oncol. 2019 14 237 246 [PMID: 30830551 DOI: 10.1007/s11523-019-00629-5].
    [Google Scholar]
  91. Hallberg B. Palmer R.H. The role of the ALK receptor in cancer biology. Ann. Oncol. 2016 27 Suppl. 3 iii4 iii15 [PMID: 27573755 DOI: 10.1093/annonc/mdw301]. 10.1093/annonc/mdw301
    [Google Scholar]
  92. Drilon A. Siena S. Ou S.H.I. Patel M. Ahn M.J. Lee J. Bauer T.M. Farago A.F. Wheler J.J. Liu S.V. Doebele R. Giannetta L. Cerea G. Marrapese G. Schirru M. Amatu A. Bencardino K. Palmeri L. Sartore-Bianchi A. Vanzulli A. Cresta S. Damian S. Duca M. Ardini E. Li G. Christiansen J. Kowalski K. Johnson A.D. Patel R. Luo D. Chow-Maneval E. Hornby Z. Multani P.S. Shaw A.T. De Braud F.G. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017 7 4 400 409 [PMID: 28183697 DOI: 10.1158/2159-8290.CD-16-1237]. 10.1158/2159‑8290.CD‑16‑1237
    [Google Scholar]
  93. Davis J.L. Ripley R.T. Postgastrectomy syndromes and nutritional con- siderations following gastric surgery. Surg. Clin. North Am. 2017 97 2 277 293 10.1016/j.suc.2016.11.005
    [Google Scholar]
  94. Hiki N. Nunobe S. Kubota T. Jiang X. Function-preserving gastrectomy for early gastric cancer. Ann. Surg. Oncol. 2013 20 8 2683 2692 10.1245/s10434‑013‑2931‑8
    [Google Scholar]
  95. Cunningham D. Allum W.H. Stenning S.P. Thompson J.N. Van de Velde C.J.H. Nicolson M. Scarffe J.H. Lofts F.J. Falk S.J. Iveson T.J. Smith D.B. Langley R.E. Verma M. Weeden S. Chua Y.J. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 2006 355 1 11 20 10.1056/NEJMoa055531
    [Google Scholar]
  96. Sasako M. Sakuramoto S. Katai H. Kinoshita T. Furukawa H. Yamaguchi T. Nashimoto A. Fujii M. Nakajima T. Ohashi Y. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J. Clin. Oncol. 2011 29 33 4387 4393 10.1200/JCO.2011.36.5908
    [Google Scholar]
  97. Soetikno R. Kaltenbach T. Yeh R. Gotoda T. Endoscopic mucosal resection for early cancers of the upper gastrointestinal tract. J. Clin. Oncol. 2005 23 20 4490 4498 10.1200/JCO.2005.19.935
    [Google Scholar]
  98. Hasuike N. Ono H. Boku N. Mizusawa J. Takizawa K. Fukuda H. Oda I. Doyama H. Kaneko K. Hori S. Iishi H. Kurokawa Y. Muto M. A non-randomized confirmatory trial of an expanded indication for endoscopic submucosal dissection for intestinal-type gastric cancer (cT1a): the Japan Clinical Oncology Group study (JCOG0607). Gastric Cancer 2018 21 1 114 123 10.1007/s10120‑017‑0704‑y
    [Google Scholar]
  99. Wang F.H. Zhang X-T. Li Y-F. Tang L. Qu X-J. Ying J-E. Zhang J. Sun L-Y. Lin R-B. Qiu H. Wang C. Qiu M-Z. Cai M-Y. Wu Q. Liu H. Guan W-L. Zhou A-P. Zhang Y-J. Liu T-S. Bi F. Yuan X-L. Rao S-X. Xin Y. Sheng W-Q. Xu H-M. Li G-X. Ji J-F. Zhou Z-W. Liang H. Zhang Y-Q. Jin J. Shen L. Li J. Xu R-H. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun. (Lond.) 2021 41 8 747 795 10.1002/cac2.12193
    [Google Scholar]
  100. Katai H. Mizusawa J. Katayama H. Morita S. Yamada T. Bando E. Ito S. Takagi M. Takagane A. Teshima S. Koeda K. Nunobe S. Yoshikawa T. Terashima M. Sasako M. Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912): a multicentre, non-inferiority, phase 3 randomised controlled trial. Lancet Gastroenterol. Hepatol. 2020 5 2 142 151 10.1016/S2468‑1253(19)30332‑2
    [Google Scholar]
  101. Kim H-H. Effect of laparoscopic distal gastrectomy vs open distal gas- trectomy on long-term survival among patients with stage I gastric cancer: the KLASS-01 randomized clinical trial. JAMA Oncol. 2019 5 506 513 10.1001/jamaoncol.2018.6727
    [Google Scholar]
  102. Cats A. Jansen E.P.M. van Grieken N.C.T. Sikorska K. Lind P. Nordsmark M. Meershoek-Klein Kranenbarg E. Boot H. Trip A.K. Swellengrebel H.A.M. van Laarhoven H.W.M. Putter H. van Sandick J.W. van Berge Henegouwen M.I. Hartgrink H.H. van Tinteren H. van de Velde C.J.H. Verheij M. Van Coevorden F. Vanhoutvin S. Hulshof M.C.C.M. Loosveld O.J.L. Ten Tije A.B.J. Erdkamp F.L.G. Warmerdam F.A.R.M. Van der Peet D.L. Verheul H.M.W. Boerma D. Los M. Slot A. Houtsma D. Portielje J.E.A. Blaisse R.J.B. Spillenaar Bilgen E.J. Polée M.B. Geenen M.M. Braak J.P.B.M. Neelis K.J. Slingerland M. Jansen R.L.H. Buijsen J. Beeker A. Eijsbouts Q.A.J. Van Riel J.M.G.H. Rozema T. Van Spronsen D.J. Meerum Terwogt J.M. Tanis B.C. Van der Torren-Conze A.M.E. Van Hilligersberg R. Koopman M. Den Boer M.O. Creemers G-J. Van der Sangen M. Rentinck M.E.M. Van den Berg H.P. Jonkers G.J.P.M. Grootenboers D. Vulink A.J.E. Hovenga S. Van der Mijle H.C.J. Baars A. Haringhuizen A.W. Appels M.I.E. Rietbroek R.C. Hendriksen E.M. Legdeur M-C.J.C. Ten Bokkel Huinink D. Van Dobbenburgh O.A. Smit J.M. Van Bochove A. Veldhuis G-J. Muller E.W. Bonenkamp J.H.J. Braam P.M. De Boer J. Van Halteren H.K. Valster F.A.A. Imholz A.L.T. Van Dijk M.A. Van der Gaast A. Otten J.H-M.M.B. Ceha H.M. Glimelius B. Lagerbäck C. Perman M. Johnsson A. Borg D. Nielsen N.H. Piwowar A. Elmlund M. Hörberg H. Edlund P. Johansson B. Flygare P. Jespersen M.L. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018 19 5 616 628 10.1016/S1470‑2045(18)30132‑3
    [Google Scholar]
  103. Yu J. Huang C. Sun Y. Su X. Cao H. Hu J. Wang K. Suo J. Tao K. He X. Wei H. Ying M. Hu W. Du X. Hu Y. Liu H. Zheng C. Li P. Xie J. Liu F. Li Z. Zhao G. Yang K. Liu C. Li H. Chen P. Ji J. Li G. Effect of laparoscopic vs open distal gastrectomy on 3-year disease- free survival in patients with locally advanced gastric cancer: the CLASS-01 randomized clinical trial. JAMA 2019 321 20 1983 1992 10.1001/jama.2019.5359
    [Google Scholar]
  104. Hyung W.J. Yang H-K. Park Y-K. Lee H-J. An J.Y. Kim W. Kim H-I. Kim H-H. Ryu S.W. Hur H. Kim M-C. Kong S-H. Cho G.S. Kim J-J. Park D.J. Ryu K.W. Kim Y.W. Kim J.W. Lee J-H. Han S-U. Long-term outcomes of laparoscopic distal gastrectomy for locally advanced gastric cancer: the KLASS-02-RCT randomized clinical trial. J. Clin. Oncol. 2020 38 28 3304 3313 10.1200/JCO.20.01210
    [Google Scholar]
  105. Song Z. Wu Y. Yang J. Yang D. Fang X. Progress in the treatment of advanced gastric cancer. Tumour Biol. 2017 39 7 10.1177/1010428317714626
    [Google Scholar]
  106. Li R. Hou W-H. Chao J. Woo Y. Glaser S. Amini A. Nelson R.A. Chen Y-J. Chemoradiation improves survival compared with chemotherapy alone in unresected nonmetastatic gastric cancer. J. Natl. Compr. Canc. Netw. 2018 16 8 950 958 10.6004/jnccn.2018.7030
    [Google Scholar]
  107. Tepper J. Krasna M.J. Niedzwiecki D. Hollis D. Reed C.E. Goldberg R. Kiel K. Willett C. Sugarbaker D. Mayer R. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J. Clin. Oncol. 2008 26 7 1086 1092 10.1200/JCO.2007.12.9593
    [Google Scholar]
  108. Ajani J.A. Mansfield P.F. Crane C.H. Wu T.T. Lunagomez S. Lynch P.M. Janjan N. Feig B. Faust J. Yao J.C. Nivers R. Morris J. Pisters P.W. Paclitaxel-based chemoradiotherapy in localized gastric carci- noma: degree of pathologic response and not clinical parameters dictated patient outcome. J. Clin. Oncol. 2005 23 6 1237 1244 10.1200/JCO.2005.01.305
    [Google Scholar]
  109. Glimelius B. Ekström K. Hoffman K. Graf W. Sjödén P-O. Haglund U. Svensson C. Enander L-K. Linné T. Sellsröm H. Heuman R. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann. Oncol. 1997 8 2 163 168 10.1023/A:1008243606668
    [Google Scholar]
  110. Abdelfatah E. Kerner Z. Nanda N. Ahuja N. Epigenetic therapy in gastrointestinal cancer: the right combination. Therap. Adv. Gastroenterol. 2016 9 4 560 579 10.1177/1756283X16644247
    [Google Scholar]
  111. Hidalgo M. Amant F. Biankin A.V. Budinská E. Byrne A.T. Caldas C. Clarke R.B. de Jong S. Jonkers J. Mælandsmo G.M. Roman-Roman S. Seoane J. Trusolino L. Villanueva A. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014 4 9 998 1013 10.1158/2159‑8290.CD‑14‑0001
    [Google Scholar]
  112. Clevers H. Modeling development and disease with organoids. Cell 2016 165 7 1586 1597 10.1016/j.cell.2016.05.082
    [Google Scholar]
  113. Hecht J.R. Bang Y.J. Qin S.K. Chung H.C. Xu J.M. Park J.O. Jeziorski K. Shparyk Y. Hoff P.M. Sobrero A. Salman P. Li J. Protsenko S.A. Wainberg Z.A. Buyse M. Afenjar K. Houé V. Garcia A. Kaneko T. Huang Y. Khan-Wasti S. Santillana S. Press M.F. Slamon D. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC—a randomized phase III trial. J. Clin. Oncol. 2016 34 5 443 451 10.1200/JCO.2015.62.6598
    [Google Scholar]
  114. Satoh T Xu RH Chung HC Phase III,randomized, double-blind, multicenter, placebo (P)- controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET- 1 study. J Clin Oncol 2015;33:4000., phase III study. J. Clin. Oncol. 2014 32 2039 2049 10.1200/JCO.2013.53.6136
    [Google Scholar]
  115. Cunningham D. Tebbutt N.C. Davidenko I. Murad A.M. Al-Batran S-E. Ilson D.H. Tjulandin S. Gotovkin E. Karaszewska B. Bondarenko I. Tejani M.A. Udrea A.A. Tehfe M.A. Baker N. Oliner K.S. Zhang Y. Hoang T. Sidhu R. Catenacci D.V.T. Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study. J. Clin. Oncol. 2015 33 15_suppl 4000 10.1200/jco.2015.33.15_suppl.4000
    [Google Scholar]
  116. Shah M.A. Bang Y.J. Lordick F. Tabernero J. Chen M. Hack S.P. Phan S-C. Shames D.S. Cunningham D. METGastric: A phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC). J. Clin. Oncol. 2015 33 15_suppl 4012 10.1200/jco.2015.33.15_suppl.4012
    [Google Scholar]
  117. Pectasides E. Genomic alterations and targeted therapy in gastric and esophageal adenocarcinoma. Clin. Ther. 2016 38 7 1589 1599 10.1016/j.clinthera.2016.03.016
    [Google Scholar]
  118. Nordstrom J.L. Gorlatov S. Zhang W. Yang Y. Huang L. Burke S. Li H. Ciccarone V. Zhang T. Stavenhagen J. Koenig S. Stewart S.J. Moore P.A. Johnson S. Bonvini E. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties. Breast Cancer Res. 2011 13 6 R123 10.1186/bcr3069
    [Google Scholar]
  119. Shinde A. Li R. Amini A. Glaser S. Can immunotherapy replace radiotherapy in melanoma brain metastases? J. Clin. Oncol. 2019 37 12 1030 1031 10.1200/JCO.18.01982
    [Google Scholar]
  120. Bang Y.J. Giaccone G. Im S.A. Oh D.Y. Bauer T.M. Nordstrom J.L. Li H. Chichili G.R. Moore P.A. Hong S. Stewart S.J. Baughman J.E. Lechleider R.J. Burris H.A. First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. Ann. Oncol. 2017 28 4 855 861 10.1093/annonc/mdx002
    [Google Scholar]
  121. Catenacci D.V.T. Kang Y-K. Park H. Uronis H.E. Lee K-W. Ng M.C.H. Enzinger P.C. Park S.H. Gold P.J. Lacy J. Hochster H.S. Oh S.C. Kim Y.H. Marrone K.A. Kelly R.J. Juergens R.A. Kim J.G. Bendell J.C. Alcindor T. Sym S.J. Song E-K. Chee C.E. Chao Y. Kim S. Lockhart A.C. Knutson K.L. Yen J. Franovic A. Nordstrom J.L. Li D. Wigginton J. Davidson-Moncada J.K. Rosales M.K. Bang Y-J. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial. Lancet Oncol. 2020 21 8 1066 1076 10.1016/S1470‑2045(20)30326‑0
    [Google Scholar]
  122. Catenacci D.V.T. Kang Y-K. Yoon H.H. Shim B.Y. Kim S.T. Oh D-Y. Spira A.I. Ulahannan S.V. Avery E.J. Boland P.M. Chao J. Chung H.C. Gardner F. Klempner S.J. Lee K-W. Oh S.C. Peguero J. Sonbol M.B. Shen L. Moehler M. Sun J. Li D. Rosales M.K. Park H. Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A. ESMO Open 2022 7 5 100563 10.1016/j.esmoop.2022.100563
    [Google Scholar]
  123. Ku G. Elimova E. Denlinger C.S. Mehta R. Lee K-W. Iqbal S. Kang Y-K. Oh D-Y. Rha S.Y. Kim Y.H. Seol Y.M. Mwatha T. Grim J. Ajani J.A. 1380P Phase (Ph) II study of zanidatamab + chemotherapy (chemo) in first-line (1L) HER2 expressing gastroesophageal adenocarcinoma (GEA). Ann. Oncol. 2021 32 S1044 S1045 10.1016/j.annonc.2021.08.1489
    [Google Scholar]
  124. Tabernero J. Shen L. Elimova E. Ku G. Liu T. Shitara K. Lin X. Boyken L. Li H. Grim J. Ajani J. HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma. Future Oncol. 2022 18 29 3255 3266 10.2217/fon‑2022‑0595
    [Google Scholar]
  125. Zhang J. Ji D. Cai L. Yao H. Yan M. Wang X. Shen W. Du Y. Pang H. Lai X. Zeng H. Huang J. Sun Y. Peng X. Xu J. Yang J. Yang F. Xu T. Hu X. First-in-human HER2-targeted bispecific antibody KN026 for the treatment of patients with HER2-positive metastatic breast cancer: results from a phase I Study. Clin. Cancer Res. 2022 28 4 618 628 10.1158/1078‑0432.CCR‑21‑2827
    [Google Scholar]
  126. Xu J. Liu R. Ying J. Wu J. Ye F. Xu N. Zhang Y. Zhao R. Xiang X. Wang J. Lin X. Xu H. Gao S. Luo S.X. Guo B. Li X. Su Y. Wang Q. A phase II study evaluating KN026 monotherapy in patients (pts) with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancers (GC/GEJC). J. Clin. Oncol. 2022 40 16_suppl Suppl. 4040 4040 10.1200/JCO.2022.40.16_suppl.4040
    [Google Scholar]
  127. Shen L. 1210P The preliminary efficacy and safety of KN026 combined with KN046 treatment in HER2-positive locally advanced unresectable or metastatic gastric/gastroesophageal junction cancer without prior systemic treatment in a phase II study. Ann. Oncol. 2022 33 S1102 10.1016/j.annonc.2022.07.1328
    [Google Scholar]
  128. Kulukian A. Lee P. Taylor J. Rosler R. de Vries P. Watson D. Forero-Torres A. Peterson S. Preclinical activity of HER2-selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models. Mol. Cancer Ther. 2020 19 4 976 987 10.1158/1535‑7163.MCT‑19‑0873
    [Google Scholar]
  129. Catenacci D.V.T. Strickler J.H. Nakamura Y. Shitara K. Janjigian Y.Y. Barzi A. Bekaii-Saab T.S. Lenz H-J. Chung H.C.C. Tabernero J. Yoshino T. Siena S. Mayor J.G. Palanca-Wessels M.C. Xie D. Marshall J. MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma—Trial in progress. J. Clin. Oncol. 2022 40 4_suppl Suppl. TPS371 10.1200/JCO.2022.40.4_suppl.TPS371
    [Google Scholar]
  130. Wu X. Huang S. HER2-specific chimeric antigen receptor-engineered natural killer cells combined with apatinib for the treatment of gastric cancer. Bull. Cancer 2019 106 11 946 958 10.1016/j.bulcan.2019.03.012
    [Google Scholar]
  131. Smyth E.C. Nilsson M. Grabsch H.I. van Grieken N.C.T. Lordick F. Gastric cancer. Lancet 2020 396 10251 635 648 10.1016/S0140‑6736(20)31288‑5
    [Google Scholar]
  132. Casak S.J. Fashoyin-Aje I. Lemery S.J. Zhang L. Jin R. Li H. Zhao L. Zhao H. Zhang H. Chen H. He K. Dougherty M. Novak R. Kennett S. Khasar S. Helms W. Keegan P. Pazdur R. FDA approval summary: ramucirumab for gastric cancer. Clin. Cancer Res. 2015 21 15 3372 3376 10.1158/1078‑0432.CCR‑15‑0600
    [Google Scholar]
  133. Fuchs C.S. Tomasek J. Yong C.J. Dumitru F. Passalacqua R. Goswami C. Safran H. dos Santos L.V. Aprile G. Ferry D.R. Melichar B. Tehfe M. Topuzov E. Zalcberg J.R. Chau I. Campbell W. Sivanandan C. Pikiel J. Koshiji M. Hsu Y. Liepa A.M. Gao L. Schwartz J.D. Tabernero J. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014 383 9911 31 39 10.1016/S0140‑6736(13)61719‑5
    [Google Scholar]
  134. Wilke H. Muro K. Van Cutsem E. Oh S-C. Bodoky G. Shimada Y. Hironaka S. Sugimoto N. Lipatov O. Kim T-Y. Cunningham D. Rougier P. Komatsu Y. Ajani J. Emig M. Carlesi R. Ferry D. Chandrawansa K. Schwartz J.D. Ohtsu A. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014 15 11 1224 1235 10.1016/S1470‑2045(14)70420‑6
    [Google Scholar]
  135. Xu R.H. Zhang Y. Pan H. Feng J. Zhang T. Liu T. Qin Y. Qin S. Yin X. Liu B. Ba Y. Yang N. Voon P.J. Tanasanvimon S. Zhou C. Zhang W.L. Shen L. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial. Lancet Gastroenterol. Hepatol. 2021 6 12 1015 1024 10.1016/S2468‑1253(21)00313‑7
    [Google Scholar]
  136. Fuchs C.S. Shitara K. Di Bartolomeo M. Lonardi S. Al-Batran S-E. Van Cutsem E. Ilson D.H. Alsina M. Chau I. Lacy J. Ducreux M. Mendez G.A. Alavez A.M. Takahari D. Mansoor W. Enzinger P.C. Gorbounova V. Wainberg Z.A. Hegewisch-Becker S. Ferry D. Lin J. Carlesi R. Das M. Shah M.A. Luft A.V. Karaseva N.A. Kowalyszyn R.D. Hernandez C.A. Csoszi T. De Vita F. Pfeiffer P. Sugimoto N. Kocsis J. Csilla A. Bodoky G. Garnica Jaliffe G. Protsenko S. Madi A. Wojcik E. Brenner B. Folprecht G. Sarosiek T. Peltola K.J. Bono P. Ayala H. Aprile G. Gerardo C.G. Huitzil Melendez F.D. Falcone A. Di Costanzo F. Tehfe M. Mineur L. García Alfonso P. Obermannova R. Senellart H. Petty R. Samuel L. Acs P.I. Hussein M.A. Nechaeva M.N. Erdkamp F.L.G. Won E. Bendell J.C. Gallego Plazas J. Lorenzen S. Melichar B. Escudero M.A. Pezet D. Phelip J-M. Kaen D.L. Reeves J.A.J. Longo Muñoz F. Madhusudan S. Barone C. Fein L.E. Gomez Villanueva A. Hebbar M. Prausova J. Visa Turmo L. Vidal Barrull J. Yilmaz M.K.N. Beny A. Van Laarhoven H.M.W. DiCarlo B.A. Esaki T. Fujitani K. Geboes K. Geva R. Kadowaki S. Leong S. Machida N. Raj M.S. Ramirez Godinez F.J. Ruzsa A. Ford H. Lawler W.E. Maisey N.R. Petera J. Shacham-Shmueli E. Sinapi I. Yamaguchi K. Hara H. Beck J.T. Błasińska-Morawiec M. Villalobos Valencia R. Alcindor T. Bajaj M. Berry S. Gomez C.M. Dammrich D. Patel R. Taieb J. Ten Tije A.J. Burkes R.L. Cabanillas F. Firdaus I. Chua C.C. Hironaka S. Hofheinz R-D. Lim H.J. Nordsmark M. Piko B. Verma U. Wadsley J. Yukisawa S. Gutiérrez Delgado F. Denlinger C.S. Kallio R. Pikiel J. Wojcik-Tomaszewska J. Brezden-Masley C. Jang R.W-J. Pribylova J. Sakai D. Bartoli M.A. Cats A. Grootscholten M.I. Dichmann R.A. Hool H. Shaib W. Tsuji A. Van den Eynde M. Velez-Cortez H. Asmis T.R. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 20 3 420 435 10.1016/S1470‑2045(18)30791‑5
    [Google Scholar]
  137. Ohtsu A. Shah M.A. Van Cutsem E. Rha S.Y. Sawaki A. Park S.R. Lim H.Y. Yamada Y. Wu J. Langer B. Starnawski M. Kang Y-K. Bevacizumab in combination with chemotherapy as first- line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J. Clin. Oncol. 2011 29 30 3968 3976 10.1200/JCO.2011.36.2236
    [Google Scholar]
  138. Pavlakis N. Shitara K. Sjoquist K.M. Martin A.J. Jaworski A. Yip S. Bang Y-J. Alcindor T. O’Callaghan C.J. Tebbutt N.C. Strickland A. Rha S.Y. Lee K-W. Zalcberg J.R. Price T.J. Simes J. Goldstein D. INTEGRATE IIa: A randomised, double-blind, phase III study of regorafenib versus placebo in refractory advanced gastro-oesophageal cancer (AGOC)—A study led by the Australasian Gastro-intestinal Trials Group (AGITG). J. Clin. Oncol. 2023 41 4_suppl LBA294 10.1200/JCO.2023.41.4_suppl.LBA294
    [Google Scholar]
  139. Fukuoka S. Hara H. Takahashi N. Kojima T. Kawazoe A. Asayama M. Yoshii T. Kotani D. Tamura H. Mikamoto Y. Hirano N. Wakabayashi M. Nomura S. Sato A. Kuwata T. Togashi Y. Nishikawa H. Shitara K. Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase ib trial (REGONIVO, EPOC1603). J. Clin. Oncol. 2020 38 18 2053 2061 10.1200/JCO.19.03296
    [Google Scholar]
  140. Kawazoe A. Fukuoka S. Nakamura Y. Kuboki Y. Wakabayashi M. Nomura S. Mikamoto Y. Shima H. Fujishiro N. Higuchi T. Sato A. Kuwata T. Shitara K. Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial. Lancet Oncol. 2020 21 8 1057 1065 10.1016/S1470‑2045(20)30271‑0
    [Google Scholar]
  141. Li J. Qin S. Xu J. Xiong J. Wu C. Bai Y. Liu W. Tong J. Liu Y. Xu R. Wang Z. Wang Q. Ouyang X. Yang Y. Ba Y. Liang J. Lin X. Luo D. Zheng R. Wang X. Sun G. Wang L. Zheng L. Guo H. Wu J. Xu N. Yang J. Zhang H. Cheng Y. Wang N. Chen L. Fan Z. Sun P. Yu H. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junc- tion. J. Clin. Oncol. 2016 34 13 1448 1454 10.1200/JCO.2015.63.5995
    [Google Scholar]
  142. Kang Y.K. Kang W.K. Di Bartolomeo M. Chau I. Yoon H.H. Cascinu S. Ryu M-H. Kim J.G. Lee K-W. Oh S.C. Takashima A. Kryzhanivska A. Chao Y. Vladimirov V. Evesque L. Schenker M. McGinn A. Sankar N. Wyrwicz L. Boku N. Randomized phase III ANGEL study of rivoceranib (apatinib) + best supportive care (BSC) vs placebo + BSC in patients with advanced/metastatic gastric cancer who failed ≥2 prior chemotherapy regimens. Ann. Oncol. 2019 30 v877 v878 10.1093/annonc/mdz394.034
    [Google Scholar]
  143. Zhang Y. A phase Ib/II study of fruquintinib in combination with paclitaxel as the second-line therapy for advanced gastric cancer. Cancer Commun. 2022 43 1 150 153
    [Google Scholar]
  144. Luo H. Xu G. Li C. He L. Luo L. Wang Z. Jing B. Deng Y. Jin Y. Li Y. Li B. Tan W. He C. Seeruttun S.R. Wu Q. Huang J. Huang D. Chen B. Lin S. Chen Q. Yuan C. Chen H. Pu H. Zhou F. He Y. Xu R. Tang Y. Ma D. Yin X. Deng Y. Yuan Y. Li M. Hu W. Chen D. Li G. Liu Q. Tan P. Fan S. Shi M. Su W. Xu R.H. Real-time artificial intelligence for detection of upper gastrointestinal cancer by endoscopy: a multicentre, case-control, diagnostic study. Lancet Oncol. 2019 20 12 1645 1654 10.1016/S1470‑2045(19)30637‑0
    [Google Scholar]
/content/journals/ccdt/10.2174/0115680096333058241114064802
Loading
Molecular-targeted Therapy for Precision Medicine in Gastrointestinal Cancer: Advancement in Cancer Targeting Strategies
Bentham Science Publishers ; https://doi.org/10.2174/0115680096333058241114064802
/content/journals/ccdt/10.2174/0115680096333058241114064802
/content/journals/ccdt/10.2174/0115680096333058241114064802
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: Gastric cancer ; therapeutic method ; precision medicine ; xenografts ; drug targets ; clinical trials

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test